Sun Pharma Reportedly Eyes $10B Organon Deal, Company Calls Rumors “Speculative”

Sun Pharmaceutical Industries Ltd, India’s largest drugmaker by market value, is reportedly exploring a massive acquisition that could reshape its presence in the United States. According to a report referenced by NewsBytes, Sun Pharma is considering a deal to buy Organon, a US-based company focused on women’s health and biosimilars, in a transaction that could be worth around $10 billion including debt.

If it moves forward, this would become the biggest cross-border acquisition in the Indian pharmaceutical industry, and one of the largest deals Sun Pharma has pursued in years.

Why Organon matters to Sun Pharma

Organon is known as a women’s health specialist and has been expanding into the growing biosimilars market. The company was spun off from MSD (Merck Sharp & Dohme) in 2021 and started its independent journey with $9.5 billion in debt, later continuing to build its portfolio through acquisitions.

One key example mentioned in the report is Organon’s $1.2 billion acquisition of Dermavant, Roivant’s immuno-dermatology business, completed in September 2024.

For Sun Pharma, the attraction is clear: a deal of this size could sharply strengthen its US footprint and expand its capabilities in areas that are becoming more competitive and profitable globally.

Advisors are reportedly involved

The report says Sun Pharma’s advisors, including a European bank, are working on a financial plan that could be presented to Organon’s board.

The discussions appear to be part of a broader period where Organon has been connected to sale talk and restructuring expectations, especially after challenges affected its stock performance.

Organon has faced turbulence

Organon has recently dealt with serious internal pressure. The report notes the company’s stock dropped 20.9% on October 27 following allegations tied to sales malpractice. After that, CEO Kevin Ali resigned, and Joseph Morrissey was appointed interim CEO while the company searched for a permanent replacement.

Despite this turmoil, Organon shares reportedly gained strong momentum recently, rising 28.1% over the past month, driven by expectations around potential sale discussions.

Sun Pharma’s financial position

Sun Pharma’s market value is listed at about $45 billion. The company reported FY25 revenue of ₹52,041 crore and an EBITDA of ₹15,300 crore (about $1.82 billion).

The report also highlights Sun Pharma’s US performance, saying its innovative products portfolio in the American market rose to $1.21 billion in FY25, led by its flagship plaque psoriasis brand Ilumya.

Talks have reportedly restarted

According to the report, Sun Pharma has been engaged with Organon since Organon stepped up its divestment program last year. However, the discussions reportedly slowed earlier due to valuation concerns, and only restarted after Organon’s share price fell.

Market impact and biosimilars angle

The biosimilar space is already dominated by major players, and the report suggests a Sun Pharma–Organon combination could shift competition in this segment. It also mentions Organon’s biosimilars manufacturing partner Samsung Bioepis, which was previously rumored to be interested, but later denied being a bidder.

Sun Pharma issues clarification

Importantly, after these reports circulated, Sun Pharma issued a clarification saying the Organon acquisition reports were “speculative in nature.” This signals that the company is not confirming any finalized deal.

Read More News:  Click Here